Investigational and Experimental Drugs to Treat Obsessive-Compulsive Disorder

References

• Ruscio AM, Stein DJ, Chiu WT, Kessler RC. The epidemiology of obsessive-compulsive disorder in the national comorbidity survey replication. Mol Psychiatry. 2010;15(1):53–63. doi:10.1038/mp.2008.94
   PubMed Web of Science ®Google Scholar
• Volavka J, Neziroglu F, Yaryura-Tobias JA. Clomipramine and imipramine in obsessive-compulsive disorder. Psychiatry Res. 1985;14(1):85–93. doi:10.1016/0165-1781(85)90092-7
   PubMed Web of Science ®Google Scholar
• Fineberg NA, Reghunandanan S, Simpson HB, et al. Obsessive-compulsive disorder (OCD): practical strategies for pharmacological and somatic treatment in adults. Psychiatry Res. 2015;227(1):114–125. doi:10.1016/j.psychres.2014.12.003
   PubMed Web of Science ®Google Scholar
• Skapinakis P, Caldwell DM, Hollingworth W, et al. Pharmacological and psychotherapeutic interventions for management of obsessive-compulsive disorder in adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2016;3(8):730–739. doi:10.1016/S2215-0366(16)30069-4
   PubMed Web of Science ®Google Scholar
• Pallanti S, Grassi G, Cantisani A. Emerging drugs to treat obsessive-compulsive disorder. Expert Opin Emerg Drugs. 2014;19(1):67–77. doi:10.1517/14728214.2014.875157
   PubMed Web of Science ®Google Scholar
• Pallanti S, Hollander E, Bienstock C, et al. Treatment non-response in OCD: methodological issues and operational definitions. Int J Neuropsychopharmacol. 2002;5(2):181–191. doi:10.1017/S1461145702002900
   PubMed Web of Science ®Google Scholar
• Grassi G, Pallanti S. Current and up-and-coming pharmacotherapy for obsessive-compulsive disorder in adults. Expert Opin Pharmacother. 2018;19(14):1541–1550. doi:10.1080/14656566.2018.1528230
   PubMed Web of Science ®Google Scholar
• Zhou DD, Zhou XX, Lv Z, et al. Comparative efficacy and tolerability of antipsychotics as augmentations in adults with treatment-resistant obsessive-compulsive disorder: a network meta-analysis. J Psychiatr Res. 2019;111:51–58. doi:10.1016/j.jpsychires.2019.01.014
   PubMed Web of Science ®Google Scholar
• Chakrabarty K, Bhattacharyya S, Christopher R, Khanna S. Glutamatergic dysfunction in OCD. Neuropsychopharmacology. 2005;30(9):1735–1740. doi:10.1038/sj.npp.1300733
   PubMed Web of Science ®Google Scholar
• Bhattacharyya S, Khanna S, Chakrabarty K, Mahadevan A, Christopher R, Shankar SK. Anti-brain autoantibodies and altered excitatory neurotransmitters in obsessive-compulsive disorder. Neuropsychopharmacology. 2009;34(12):2489–2496. doi:10.1038/npp.2009.77
   PubMed Web of Science ®Google Scholar
• Yücel M, Wood SJ, Wellard RM, et al. Anterior cingulate glutamate-glutamine levels predict symptom severity in women with obsessive-compulsive disorder. Aust N Z J Psychiatry. 2008;42(6):467–477. doi:10.1080/00048670802050546
   PubMed Web of Science ®Google Scholar
• Starck G, Ljungberg M, Nilsson M, et al. A 1H magnetic resonance spectroscopy study in adults with obsessive compulsive disorder: relationship between metabolite concentrations and symptom severity. J Neural Transm (Vienna). 2008;115(7):1051–1062. doi:10.1007/s00702-008-0045-4
   PubMed Web of Science ®Google Scholar
• Rosenberg DR, MacMaster FP, Keshavan MS, Fitzgerald KD, Stewart CM, Moore GJ. Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. J Am Acad Child Adolesc Psychiatry. 2000;39(9):1096–1103. doi:10.1097/00004583-200009000-00008
   PubMed Web of Science ®Google Scholar
• Rosenberg DR, Mirza Y, Russell A, et al. Reduced anterior cingulate glutamatergic concentrations in childhood OCD and major depression versus healthy controls. J Am Acad Child Adolesc Psychiatry. 2004;43(9):1146–1153. doi:10.1097/01.chi.0000132812.44664.2d
   PubMed Web of Science ®Google Scholar
• O’Neill J, Piacentini J, Chang S, et al. Glutamate in pediatric obsessive-compulsive disorder and response to cognitive-behavioral therapy: randomized clinical trial. Neuropsychopharmacology. 2017;42(12):2414–2422. doi:10.1038/npp.2017.77
   PubMed Web of Science ®Google Scholar
• Giménez M, Cano M, Martínez-Zalacaín I, et al. Is glutamate associated with fear extinction and cognitive behavior therapy outcome in OCD? A pilot study [published online ahead of print, 2019 Aug 20]. Eur Arch Psychiatry Clin Neurosci. 2019. doi:10.1007/s00406-019-01056-3
   Web of Science ®Google Scholar
• Rajendram R, Kronenberg S, Burton CL, Arnold PD. Glutamate genetics in obsessive-compulsive disorder: a review. J Can Acad Child Adolesc Psychiatry. 2017;26(3):205–213.
   PubMed Web of Science ®Google Scholar
• Pittenger C. Glutamatergic agents for OCD and related disorders. Curr Treat Options Psychiatry. 2015;2(3):271–283. doi:10.1007/s40501-015-0051-8
   PubMedGoogle Scholar
• Marinova Z, Chuang DM, Fineberg N. Glutamate-modulating drugs as a potential therapeutic strategy in obsessive-compulsive disorder. Curr Neuropharmacol. 2017;15(7):977–995. doi:10.2174/1570159X15666170320104237
   Web of Science ®Google Scholar
• Molero P, Ramos-Quiroga JA, Martin-Santos R, Calvo-Sánchez E, Gutiérrez-Rojas L, Meana JJ. Antidepressant efficacy and tolerability of ketamine and esketamine: a critical review. CNS Drugs. 2018;32(5):411–420. doi:10.1007/s40263-018-0519-3
   PubMed Web of Science ®Google Scholar
• Rodriguez CI, Kegeles LS, Flood P, Simpson HB. Rapid resolution of obsessions after an infusion of intravenous ketamine in a patient with treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2011;72(4):567–569. doi:10.4088/JCP.10l06653
   PubMed Web of Science ®Google Scholar
• Bloch MH, Wasylink S, Landeros-Weisenberger A, et al. Effects of ketamine in treatment-refractory obsessive-compulsive disorder. Biol Psychiatry. 2012;72(11):964–970. doi:10.1016/j.biopsych.2012.05.028
   PubMed Web of Science ®Google Scholar
• Niciu MJ, Grunschel BD, Corlett PR, Pittenger C, Bloch MH. Two cases of delayed-onset suicidal ideation, dysphoria and anxiety after ketamine infusion in patients with obsessive-compulsive disorder and a history of major depressive disorder. J Psychopharmacol. 2013;27(7):651–654. doi:10.1177/0269881113486718
   PubMed Web of Science ®Google Scholar
• Rodriguez CI, Kegeles LS, Levinson A, et al. Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept. Neuropsychopharmacology. 2013;38(12):2475–2483. doi:10.1038/npp.2013.150
   PubMed Web of Science ®Google Scholar
• Rodriguez CI, Kegeles LS, Levinson A, et al. In vivo effects of ketamine on glutamate-glutamine and gamma-aminobutyric acid in obsessive-compulsive disorder: proof of concept. Psychiatry Res. 2015;233(2):141–147.
   PubMed Web of Science ®Google Scholar
• Rodriguez CI, Wheaton M, Zwerling J, et al. Can exposure-based CBT extend the effects of intravenous ketamine in obsessive-compulsive disorder? an open-label trial. J Clin Psychiatry. 2016;77(3):408–409. doi:10.4088/JCP.15l10138
   PubMed Web of Science ®Google Scholar
• Rodriguez CI, Levinson A, Zwerling J, Vermes D, Simpson HB. Open-Label trial on the effects of memantine in adults with obsessive-compulsive disorder after a single ketamine infusion. J Clin Psychiatry. 2016;77(5):688–689. doi:10.4088/JCP.15l10318
   PubMed Web of Science ®Google Scholar
• Moskal JR, Burch R, Burgdorf JS, et al. GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists. Expert Opin Investig Drugs. 2014;23(2):243–254. doi:10.1517/13543784.2014.852536
   PubMed Web of Science ®Google Scholar
• Rodriguez CI, Zwerling J, Kalanthroff E, et al. Effect of a novel NMDA receptor modulator, rapastinel (Formerly GLYX-13), in OCD: proof of concept. Am J Psychiatry. 2016;173(12):1239–1241.
   PubMed Web of Science ®Google Scholar
• Linkovski O, Shen H, Zwerling J, et al. Effects of rapastinel (Formerly GLYX-13) on serum brain-derived neurotrophic factor in obsessive-compulsive disorder. J Clin Psychiatry. 2018;79(1):17l11824. doi:10.4088/JCP.17l11824
   Web of Science ®Google Scholar
• Poyurovsky M, Weizman R, Weizman A, Koran L. Memantine for treatment-resistant OCD. Am J Psychiatry. 2005;162(11):2191–2192. doi:10.1176/appi.ajp.162.11.2191-a
   PubMed Web of Science ®Google Scholar
• Pasquini M, Biondi M. Memantine augmentation for refractory obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(6):1173–1175. doi:10.1016/j.pnpbp.2006.04.013
   PubMed Web of Science ®Google Scholar
• Hezel DM, Beattie K, Stewart SE. Memantine as an augmenting agent for severe pediatric OCD. Am J Psychiatry. 2009;166(2):237. doi:10.1176/appi.ajp.2008.08091427
   PubMed Web of Science ®Google Scholar
• Pekrul SR, Fitzgerald KD. Memantine Augmentation in a Down’s Syndrome Adolescent with Treatment- Resistant Obsessive-Compulsive Disorder. J Child Adolesc Psychopharmacol. 2015;25(7):593–595. doi:10.1089/cap.2015.0073
   PubMed Web of Science ®Google Scholar
• Aboujaoude E, Barry JJ, Gamel N. Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. J Clin Psychopharmacol. 2009;29(1):51–55. doi:10.1097/JCP.0b013e318192e9a4
   PubMed Web of Science ®Google Scholar
• Feusner JD, Kerwin L, Saxena S, Bystritsky A. Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial. Psychopharmacol Bull. 2009;42(1):81–93.
   PubMed Web of Science ®Google Scholar
• Bakhla AK, Verma V, Soren S, Sarkhel S, Chaudhury S. An open-label trial of memantine in treatment-resistant obsessive-compulsive disorder. Ind Psychiatry J. 2013;22(2):149–152. doi:10.4103/0972-6748.132930
   PubMedGoogle Scholar
• Stewart SE, Jenike EA, Hezel DM, et al. A single-blinded case-control study of memantine in severe obsessive-compulsive disorder. J Clin Psychopharmacol. 2010;30(1):34–39. doi:10.1097/JCP.0b013e3181c856de
   PubMed Web of Science ®Google Scholar
• Haghighi M, Jahangard L, Mohammad-Beigi H, et al. In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD). Psychopharmacology (Berl). 2013;228(4):633–640. doi:10.1007/s00213-013-3067-z
   PubMed Web of Science ®Google Scholar
• Ghaleiha A, Entezari N, Modabbernia A, et al. Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study. J Psychiatr Res. 2013;47(2):175–180. doi:10.1016/j.jpsychires.2012.09.015
   PubMed Web of Science ®Google Scholar
• Modarresi A, Sayyah M, Razooghi S, Eslami K, Javadi M, Kouti L. Memantine augmentation improves symptoms in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a randomized controlled trial. Pharmacopsychiatry. 2018;51(6):263–269. doi:10.1055/s-0043-120268
   PubMed Web of Science ®Google Scholar
• Modarresi A, Chaibakhsh S, Koulaeinejad N, Koupaei SR. A systematic review and meta-analysis: memantine augmentation in moderate to severe obsessive-compulsive disorder. Psychiatry Res. 2019;282:112602. doi:10.1016/j.psychres.2019.112602
   PubMed Web of Science ®Google Scholar
• Sansone RA, Sansone LA. Getting a Knack for NAC: N-Acetyl-Cysteine. Innov Clin Neurosci. 2011;8(1):10–14.
   Google Scholar
• Grant JE, Odlaug BL, Kim SW. N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Arch Gen Psychiatry. 2009;66(7):756–763. doi:10.1001/archgenpsychiatry.2009.60
   PubMed Web of Science ®Google Scholar
• Grant JE, Chamberlain SR, Redden SA, Leppink EW, Odlaug BL, Kim SW. N-Acetylcysteine in the treatment of excoriation disorder: a randomized clinical trial. JAMA Psychiatry. 2016;73(5):490–496. doi:10.1001/jamapsychiatry.2016.0060
   PubMed Web of Science ®Google Scholar
• Costa DLC, Diniz JB, Requena G, et al. Randomized, double-blind, placebo-controlled trial of N-Acetylcysteine augmentation for treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2017;78(7):e766–e773. doi:10.4088/JCP.16m11101
   PubMed Web of Science ®Google Scholar
• Sarris J, Oliver G, Camfield DA, et al. N-Acetyl Cysteine (NAC) in the treatment of obsessive-compulsive disorder: a 16-week, double-blind, randomised, placebo-controlled study. CNS Drugs. 2015;29(9):801–809. doi:10.1007/s40263-015-0272-9
   PubMed Web of Science ®Google Scholar
• Afshar H, Roohafza H, Mohammad-Beigi H, et al. N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2012;32(6):797–803. doi:10.1097/JCP.0b013e318272677d
   PubMed Web of Science ®Google Scholar
• Paydary K, Akamaloo A, Ahmadipour A, Pishgar F, Emamzadehfard S, Akhondzadeh S. N-acetylcysteine augmentation therapy for moderate-to-severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled trial. J Clin Pharm Ther. 2016;41(2):214–219. doi:10.1111/jcpt.12370
   PubMed Web of Science ®Google Scholar
• Ghanizadeh A, Mohammadi MR, Bahraini S, Keshavarzi Z, Firoozabadi A, Alavi Shoshtari A. Efficacy of N-Acetylcysteine augmentation on obsessive compulsive disorder: a multicenter randomized double blind placebo controlled clinical trial. Iran J Psychiatry. 2017;12(2):134–141.
   PubMedGoogle Scholar
• Li F, Welling MC, Johnson JA, et al. N-acetylcysteine for pediatric obsessive-compulsive disorder: a small pilot study. J Child Adolesc Psychopharmacol. 2020;30(1):32–37. doi:10.1089/cap.2019.0041
   PubMed Web of Science ®Google Scholar
• Shen Y, He P, Fan -Y-Y, et al. Carnosine protects against permanent cerebral ischemia in histidine decarboxylase knockout mice by reducing glutamate excitotoxicity. Free Radic Biol Med. 2010;48(5):727–735. doi:10.1016/j.freeradbiomed.2009.12.021
   Web of Science ®Google Scholar
• Rossignol DA. Novel and emerging treatments for autism spectrum disorders: a systematic review. Ann Clin Psychiatry. 2009;21(4):213–236.
   PubMed Web of Science ®Google Scholar
• Szcześniak D, Budzeń S, Kopeć W, Rymaszewska J. Anserine and carnosine supplementation in the elderly: effects on cognitive functioning and physical capacity. Arch Gerontol Geriatr. 2014;59(2):485–490. doi:10.1016/j.archger.2014.04.008
   PubMed Web of Science ®Google Scholar
• Chengappa KN, Turkin SR, DeSanti S, et al. A preliminary, randomized, double-blind, placebo-controlled trial of L-carnosine to improve cognition in schizophrenia. Schizophr Res. 2012;142(1–3):145–152. doi:10.1016/j.schres.2012.10.001
   PubMed Web of Science ®Google Scholar
• Arabzadeh S, Shahhossenie M, Mesgarpour B, et al. L-carnosine as an adjuvant to fluvoxamine in treatment of obsessive compulsive disorder: A randomized double-blind study. Hum Psychopharmacol. 2017;32(4):e2584. doi:10.1002/hup.2584
   Web of Science ®Google Scholar
• Leng Y, Fessler EB, Chuang DM. Neuroprotective effects of the mood stabilizer lamotrigine against glutamate excitotoxicity: roles of chromatin remodelling and Bcl-2 induction. Int J Neuropsychopharmacol. 2013;16(3):607–620. doi:10.1017/S1461145712000429
   PubMed Web of Science ®Google Scholar
• Bruno A, Micò U, Pandolfo G, et al. Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. J Psychopharmacol. 2012;26(11):1456–1462. doi:10.1177/0269881111431751
   PubMed Web of Science ®Google Scholar
• Khalkhali M, Aram S, Zarrabi H, Kafie M, Heidarzadeh A. Lamotrigine augmentation versus placebo in serotonin reuptake inhibitors-resistant obsessive-compulsive disorder: a randomized controlled trial. Iran J Psychiatry. 2016;11(2):104–114.
   PubMedGoogle Scholar
• Poyurovsky M, Glick I, Koran LM. Lamotrigine augmentation in schizophrenia and schizoaffective patients with obsessive-compulsive symptoms. J Psychopharmacol. 2010;24(6):861–866. doi:10.1177/0269881108099215
   PubMed Web of Science ®Google Scholar
• Sharma V, Doobay M. Lamotrigine-induced obsessive-compulsive disorder in patients with bipolar disorder. CNS Spectr. 2019;24(4):390–394. doi:10.1017/S1092852918001049
   PubMed Web of Science ®Google Scholar
• Mowla A, Khajeian AM, Sahraian A, Chohedri AH, Kashkoli F. Topiramate augmentation in resistant OCD: a double-blind placebo-controlled clinical trial. CNS Spectr. 2010;15(11):613–617. doi:10.1017/S1092852912000065
   PubMed Web of Science ®Google Scholar
• Berlin HA, Koran LM, Jenike MA, et al. Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2011;72(5):716–721. doi:10.4088/JCP.09m05266gre
   PubMed Web of Science ®Google Scholar
• Afshar H, Akuchekian S, Mahaky B, Zarean E. Topiramate augmentation in refractory obsessive-compulsive disorder: A randomized, double-blind, placebo-controlled trial. J Res Med Sci. 2014;19(10):976–981.
   PubMed Web of Science ®Google Scholar
• Greenberg WM, Benedict MM, Doerfer J, et al. Adjunctive glycine in the treatment of obsessive-compulsive disorder in adults. J Psychiatr Res. 2009;43(6):664–670. doi:10.1016/j.jpsychires.2008.10.007
   PubMed Web of Science ®Google Scholar
• de Leeuw AS, van Megen HJ, Kahn RS, Westenberg HG. d-cycloserine addition to exposure sessions in the treatment of patients with obsessive-compulsive disorder. Eur Psychiatry. 2017;40:38–44. doi:10.1016/j.eurpsy.2016.06.011
   PubMed Web of Science ®Google Scholar
• Storch EA, Wilhelm S, Sprich S, et al. Efficacy of augmentation of cognitive behavior therapy with weight-adjusted d-Cycloserine vs placebo in pediatric obsessive-compulsive disorder: a randomized clinical trial. JAMA Psychiatry. 2016;73(8):779–788. doi:10.1001/jamapsychiatry.2016.1128
   PubMed Web of Science ®Google Scholar
• Mataix-Cols D, Fernández de la Cruz L, Monzani B, et al. D-Cycloserine augmentation of exposure-based cognitive behavior therapy for anxiety, obsessive-compulsive, and posttraumatic stress disorders: a systematic review and meta-analysis of individual participant data [published correction appears in JAMA Psychiatry. 2017 May 1;74(5):542]. JAMA Psychiatry. 2017;74(5):501–510.
   PubMed Web of Science ®Google Scholar
• McGuire JF, Wu MS, Piacentini J, McCracken JT, Storch EA. A meta-analysis of D-Cycloserine in exposure-based treatment: moderators of treatment efficacy, response, and diagnostic remission. J Clin Psychiatry. 2017;78(2):196–206. doi:10.4088/JCP.15r10334
   PubMed Web of Science ®Google Scholar
• Wu PL, Tang HS, Lane HY, Tsai CA, Tsai GE. Sarcosine therapy for obsessive compulsive disorder: a prospective, open-label study. J Clin Psychopharmacol. 2011;31(3):369–374. doi:10.1097/JCP.0b013e3182189878
   PubMed Web of Science ®Google Scholar
• Grant PJ, Joseph LA, Farmer CA, et al. 12-week, placebo-controlled trial of add-on riluzole in the treatment of childhood-onset obsessive-compulsive disorder. Neuropsychopharmacology. 2014;39(6):1453–1459.
   PubMed Web of Science ®Google Scholar
• Pittenger C, Bloch MH, Wasylink S, et al. Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a pilot randomized placebo-controlled trial. J Clin Psychiatry. 2015;76(8):1075–1084. doi:10.4088/JCP.14m09123
   PubMed Web of Science ®Google Scholar
• Emamzadehfard S, Kamaloo A, Paydary K, et al. Riluzole in augmentation of fluvoxamine for moderate to severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled study. Psychiatry Clin Neurosci. 2016;70(8):332–341. doi:10.1111/pcn.12394
   PubMed Web of Science ®Google Scholar
• Khandaker GM, Dantzer R, Jones PB. Immunopsychiatry: important facts. Psychol Med. 2017;47(13):2229–2237.
   PubMed Web of Science ®Google Scholar
• Swedo SE, Leonard HL, Garvey M, et al. Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: clinical description of the first 50 cases [published correction appears in Am J Psychiatry 1998 Apr;155(4):578]. Am J Psychiatry. 1998;155(2):264–271.
   PubMed Web of Science ®Google Scholar
• Swedo SE, Leckman JF, Rose NR. From research subgroup to clinical syndrome: modifying the PANDAS criteria to describe PANS (pediatric acute-onset neuropsychiatric syndrome). Pediatr Ther. 2012;2:113. doi:10.4172/2161-0665.1000113
   Google Scholar
• Chiarello F, Spitoni S, Hollander E, Matucci Cerinic M, Pallanti S. An expert opinion on PANDAS/PANS: highlights and controversies. Int J Psychiatry Clin Pract. 2017;21(2):91–98. doi:10.1080/13651501.2017.1285941
   PubMed Web of Science ®Google Scholar
• Pearlman DM, Vora HS, Marquis BG, Najjar S, Dudley LA. Anti-basal ganglia antibodies in primary obsessive-compulsive disorder: systematic review and meta-analysis. Br J Psychiatry. 2014;205(1):8–16. doi:10.1192/bjp.bp.113.137018
   PubMed Web of Science ®Google Scholar
• Korostil M, Feinstein A. Anxiety disorders and their clinical correlates in multiple sclerosis patients. Mult Scler. 2007;13(1):67–72. doi:10.1177/1352458506071161
   PubMed Web of Science ®Google Scholar
• Bachen EA, Chesney MA, Criswell LA. Prevalence of mood and anxiety disorders in women with systemic lupus erythematosus. Arthritis Rheum. 2009;61(6):822–829. doi:10.1002/art.24519
   PubMed Web of Science ®Google Scholar
• Mataix-Cols D, Frans E, Pérez-Vigil A, et al. A total-population multigenerational family clustering study of autoimmune diseases in obsessive-compulsive disorder and Tourette’s/chronic tic disorders. Mol Psychiatry. 2018;23(7):1652–1658. doi:10.1038/mp.2017.215
   PubMed Web of Science ®Google Scholar
• Cosco TD, Pillinger T, Emam H, et al. Immune aberrations in obsessive-compulsive disorder: a systematic review and meta-analysis. Mol Neurobiol. 2019;56(7):4751–4759. doi:10.1007/s12035-018-1409-x
   PubMed Web of Science ®Google Scholar
• Attwells S, Setiawan E, Wilson AA, et al. Inflammation in the neurocircuitry of obsessive-compulsive disorder. JAMA Psychiatry. 2017;74(8):833–840. doi:10.1001/jamapsychiatry.2017.1567
   PubMed Web of Science ®Google Scholar
• Burchi E, Pallanti S. Antibiotics for PANDAS? Limited evidence: review and putative mechanisms of action. Prim Care Companion CNS Disord. 2018;20(3):17r02232.
   PubMedGoogle Scholar
• Spartz EJ, Freeman GM Jr, Brown K, Farhadian B, Thienemann M, Frankovich J. Course of neuropsychiatric symptoms after introduction and removal of nonsteroidal anti-inflammatory drugs: a pediatric observational study. J Child Adolesc Psychopharmacol. 2017;27(7):652–659. doi:10.1089/cap.2016.0179
   PubMed Web of Science ®Google Scholar
• Kimura T, Iwase M, Kondo G, et al. Suppressive effect of selective cyclooxygenase-2 inhibitor on cytokine release in human neutrophils. Int Immunopharmacol. 2003;3(10–11):1519–1528. doi:10.1016/S1567-5769(03)00179-6
   Web of Science ®Google Scholar
• Strauss KI, Marini AM. Cyclooxygenase-2 inhibition protects cultured cerebellar granule neurons from glutamate-mediated cell death. J Neurotrauma. 2002;19(5):627–638. doi:10.1089/089771502753754091
   Web of Science ®Google Scholar
• Abbasi SH, Hosseini F, Modabbernia A, Ashrafi M, Akhondzadeh S. Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study. J Affect Disord. 2012;141(2–3):308–314. doi:10.1016/j.jad.2012.03.033
   PubMed Web of Science ®Google Scholar
• Sayyah M, Boostani H, Pakseresht S, Malayeri A. A preliminary randomized double-blind clinical trial on the efficacy of celecoxib as an adjunct in the treatment of obsessive-compulsive disorder. Psychiatry Res. 2011;189(3):403–406. doi:10.1016/j.psychres.2011.01.019
   PubMed Web of Science ®Google Scholar
• Shalbafan M, Mohammadinejad P, Shariat SV, et al. Celecoxib as an adjuvant to fluvoxamine in moderate to severe obsessive-compulsive disorder: a double-blind, placebo-controlled, randomized trial. Pharmacopsychiatry. 2015;48(4–5):136–140. doi:10.1055/s-0035-1549929
   PubMed Web of Science ®Google Scholar
• Amantea D, Bagetta G. Drug repurposing for immune modulation in acute ischemic stroke. Curr Opin Pharmacol. 2016;26:124–130. doi:10.1016/j.coph.2015.11.006
   PubMed Web of Science ®Google Scholar
• Rodriguez CI, Bender J Jr, Marcus SM, Snape M, Rynn M, Simpson HB. Minocycline augmentation of pharmacotherapy in obsessive-compulsive disorder: an open-label trial. J Clin Psychiatry. 2010;71(9):1247–1249. doi:10.4088/JCP.09l05805blu
   PubMed Web of Science ®Google Scholar
• Esalatmanesh S, Abrishami Z, Zeinoddini A, et al. Minocycline combination therapy with fluvoxamine in moderate-to-severe obsessive-compulsive disorder: A placebo-controlled, double-blind, randomized trial. Psychiatry Clin Neurosci. 2016;70(11):517–526. doi:10.1111/pcn.12430
   PubMed Web of Science ®Google Scholar
• Turna J, Grosman Kaplan K, Anglin R, Van Ameringen M. “What’s bugging the gut in OCD?” A review of the gut microbiome in obsessive-compulsive disorder. Depress Anxiety. 2016;33(3):171–178. doi:10.1002/da.22454
   PubMed Web of Science ®Google Scholar
• Turna J, Grosman Kaplan K, Anglin R, et al. The gut microbiome and inflammation in obsessive-compulsive disorder patients compared to age- and sex-matched controls: a pilot study [published online ahead of print, 2020 Apr 20]. Acta Psychiatr Scand. 2020. doi:10.1111/acps.13175
   Web of Science ®Google Scholar
• Naseribafrouei A, Hestad K, Avershina E, et al. Correlation between the human fecal microbiota and depression. Neurogastroenterol Motil. 2014;26(8):1155–1162. doi:10.1111/nmo.12378
   PubMed Web of Science ®Google Scholar
• Jiang H, Ling Z, Zhang Y, et al. Altered fecal microbiota composition in patients with major depressive disorder. Brain Behav Immun. 2015;48:186–194. doi:10.1016/j.bbi.2015.03.016
   PubMed Web of Science ®Google Scholar
• Collins SM, Surette M, Bercik P. The interplay between the intestinal microbiota and the brain. Nat Rev Microbiol. 2012;10(11):735–742. doi:10.1038/nrmicro2876
   PubMed Web of Science ®Google Scholar
• Sudo N, Chida Y, Aiba Y, et al. Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system for stress response in mice. J Physiol. 2004;558(Pt 1):263–275. doi:10.1113/jphysiol.2004.063388
   PubMed Web of Science ®Google Scholar
• Thayer JF, Sternberg EM. Neural concomitants of immunity–focus on the vagus nerve. Neuroimage. 2009;47(3):908–910. doi:10.1016/j.neuroimage.2009.05.058
   Web of Science ®Google Scholar
• Kamada N, Núñez G. Regulation of the immune system by the resident intestinal bacteria. Gastroenterology. 2014;146(6):1477–1488. doi:10.1053/j.gastro.2014.01.060
   PubMed Web of Science ®Google Scholar
• Scheepers IM, Cryan JF, Bastiaanssen TFS, et al. Natural compulsive-like behaviour in the deer mouse (Peromyscus maniculatus bairdii) is associated with altered gut microbiota composition. Eur J Neurosci. 2020;51(6):1419–1427. doi:10.1111/ejn.14610
   PubMed Web of Science ®Google Scholar
• Quagliariello A, Del Chierico F, Russo A, et al. Gut microbiota profiling and gut-brain crosstalk in children affected by pediatric acute-onset neuropsychiatric syndrome and pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections. Front Microbiol. 2018;9:675. doi:10.3389/fmicb.2018.00675
   PubMed Web of Science ®Google Scholar
• Kantak PA, Bobrow DN, Nyby JG. Obsessive-compulsive-like behaviors in house mice are attenuated by a probiotic (Lactobacillus rhamnosus GG). Behav Pharmacol. 2014;25(1):71–79. doi:10.1097/FBP.0000000000000013
   PubMed Web of Science ®Google Scholar
• Messaoudi M, Violle N, Bisson JF, Desor D, Javelot H, Rougeot C. Beneficial psychological effects of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in healthy human volunteers. Gut Microbes. 2011;2(4):256–261. doi:10.4161/gmic.2.4.16108
   PubMed Web of Science ®Google Scholar
• Axelrod J, Tomchick R. Enzymatic O-methylation of epinephrine and other catechols. J Biol Chem. 1958;233(3):702–705.
   PubMed Web of Science ®Google Scholar
• Jatana N, Apoorva N, Malik S, Sharma A, Latha N. Inhibitors of catechol-O-methyltransferase in the treatment of neurological disorders. Cent Nerv Syst Agents Med Chem. 2013;13(3):166–194. doi:10.2174/1871524913666140109113341
   Google Scholar
• Kumar P, Rai V. Catechol-O-methyltransferase gene Val158Met polymorphism and obsessive compulsive disorder susceptibility: a meta-analysis. Metab Brain Dis. 2020;35(2):241–251. doi:10.1007/s11011-019-00495-0
   Web of Science ®Google Scholar
• Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics. 1996;6(3):243–250. doi:10.1097/00008571-199606000-00007
   PubMedGoogle Scholar
• Lotta T, Vidgren J, Tilgmann C, et al. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry. 1995;34(13):4202–4210. doi:10.1021/bi00013a008
   PubMed Web of Science ®Google Scholar
• Chen J, Lipska BK, Halim N, et al. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain [published correction appears in Am J Hum Genet. 2005 Jun;76(6):1089]. Am J Hum Genet. 2004;75(5):807–821. doi:10.1086/425589
   PubMed Web of Science ®Google Scholar
• Wang Z, Xiao Z, Inslicht SS, et al. Low expression of catecholamine-O-methyl-transferase gene in obsessive-compulsive disorder. J Anxiety Disord. 2009;23(5):660–664. doi:10.1016/j.janxdis.2009.02.004
   Web of Science ®Google Scholar
• Taylor S. Association between COMT Val158Met and psychiatric disorders: A comprehensive meta-analysis. Am J Med Genet B Neuropsychiatr Genet. 2018;177(2):199–210. doi:10.1002/ajmg.b.32556
   Web of Science ®Google Scholar
• Grassi G, Pallanti S, Righi L, et al. Think twice: impulsivity and decision making in obsessive-compulsive disorder. J Behav Addict. 2015;4(4):263–272. doi:10.1556/2006.4.2015.039
   PubMed Web of Science ®Google Scholar
• Fineberg NA, Hollander E, Pallanti S, et al. Clinical advances in obsessive-compulsive disorder: a position statement by the International College of Obsessive-Compulsive Spectrum Disorders. Int Clin Psychopharmacol. 2020;35(4):173–193.
   PubMed Web of Science ®Google Scholar
• Deleu D, Northway MG, Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson’s disease. Clin Pharmacokinet. 2002;41(4):261–309. doi:10.2165/00003088-200241040-00003
   PubMed Web of Science ®Google Scholar
• Kayser RR, Snorrason I, Haney M, Lee FS, Simpson HB. The endocannabinoid system: a new treatment target for obsessive compulsive disorder? Cannabis Cannabinoid Res. 2019;4(2):77–87. doi:10.1089/can.2018.0049
   Google Scholar
• Lutz B, Marsicano G, Maldonado R, Hillard CJ. The endocannabinoid system in guarding against fear, anxiety and stress. Nat Rev Neurosci. 2015;16(12):705–718.
   Web of Science ®Google Scholar
• Szejko N, Fremer C, Müller-Vahl KR. Cannabis improves obsessive-compulsive disorder-case report and review of the literature. Front Psychiatry. 2020;11:681. doi:10.3389/fpsyt.2020.00681
   Web of Science ®Google Scholar
• Flanagan TW, Nichols CD. Psychedelics as anti-inflammatory agents. Int Rev Psychiatry. 2018;30(4):363–375. doi:10.1080/09540261.2018.1481827
   PubMed Web of Science ®Google Scholar
• Wilcox JA. Psilocybin and obsessive compulsive disorder. J Psychoactive Drugs. 2014;46(5):393–395. doi:10.1080/02791072.2014.963754
   PubMed Web of Science ®Google Scholar
• Moreno FA, Wiegand CB, Taitano EK, Delgado PL. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry. 2006;67(11):1735–1740. doi:10.4088/JCP.v67n1110
   PubMed Web of Science ®Google Scholar
• Nagele P, Zorumski CF, Conway C. Exploring nitrous oxide as treatment of mood disorders: basic concepts. J Clin Psychopharmacol. 2018;38(2):144–148. doi:10.1097/JCP.0000000000000837
   Web of Science ®Google Scholar
• Nagele P, Duma A, Kopec M, et al. Nitrous oxide for treatment-resistant major depression: a proof-of-concept trial. Biol Psychiatry. 2015;78(1):10–18. doi:10.1016/j.biopsych.2014.11.016
   Web of Science ®Google Scholar
• Salles G, Barrett M, Foà R, Maurer J. Rituximab in B-Cell hematologic malignancies: a review of 20 years of clinical experience. Adv Ther. 2017;34(10):2232–2273. doi:10.1007/s12325-017-0612-x
   PubMed Web of Science ®Google Scholar
• Serata D, Kotzalidis GD, Rapinesi C, et al. Are 5-HT3 antagonists effective in obsessive-compulsive disorder? A systematic review of literature. Hum Psychopharmacol. 2015;30(2):70–84. doi:10.1002/hup.2461
   PubMed Web of Science ®Google Scholar
• Mowla A, Ghaedsharaf M. Pregabalin augmentation for resistant obsessive-compulsive disorder: a double-blind placebo-controlled clinical trial. CNS Spectr. 2020;25(4):552–556. doi:10.1017/S1092852919001500
   Web of Science ®Google Scholar